1/4

SEQUENCE LISTING

<110> Bayer HealthCare AG

<120> Diagnostics and Therapeutics for Diseases Associated with Glycogen Synthase Kinase 3 beta (GSK3B)

<130> BHC 04 01 040

<160> 5

<170> PatentIn version 3.2

<210> 1

<211> 1639

<212> DNA

<213> Homo sapiens

<400> 1

atcatctata tgttaaatat ccgtgccgat ctgtcttgaa ggagaaatat atcgcttgtt 60 ttgtttttta tagtatacaa aaggagtgaa aagccaagag gacgaagtct ttttcttttt 120 cttctgtggg agaacttaat gctgcattta tcgttaacct aacaccccaa cataaagaca 180 aaaggaagaa aaggaggaag gaaggaaaag gtgattcgcg aagagagtga tcatgtcagg 240 geggeecaga accaecteet ttgeggagag etgeaageeg gtgeageage etteagettt 300 tggcagcatg aaagttagca gagacaagga cggcagcaag gtgacaacag tggtggcaac 360 tcctgggcag ggtccagaca ggccacaaga agtcagctat acagacacta aagtgattgg 420 aaatggatca tttggtgtgg tatatcaagc caaactttgt gattcaggag aactggtcgc 480 catcaagaaa gtattgcagg acaagagatt taagaatcga gagctccaga tcatgagaaa 540 gctagatcac tgtaacatag tccgattgcg ttatttcttc tactccagtg gtgagaagaa 600 660 agatgaggtc tatcttaatc tggtgctgga ctatgttccg gaaacagtat acagagttgc cagacactat agtcgagcca aacagacgct ccctgtgatt tatgtcaagt tgtatatgta 720 tcagctgttc cgaagtttag cctatatcca ttcctttgga atctgccatc gggatattaa 780 840 accgcagaac ctcttgttgg atcctgatac tgctgtatta aaactctgtg actttggaag tgcaaagcag ctggtccgag gagaacccaa tgtttcgtat atctgttctc ggtactatag 900 ggcaccagag ttgatctttg gagccactga ttatacctct agtatagatg tatggtctgc .960 tggctgtgtg ttggctgagc tgttactagg acaaccaata tttccagggg atagtggtgt 1020 ggatcagttg gtagaaataa tcaaggtcct gggaactcca acaagggagc aaatcagaga 1080 aatgaaccca aactacacag aatttaaatt ccctcaaatt aaggcacatc cttggactaa 1140 1200 ggattcgtca ggaacaggac atttcacctc aggagtgcgg gtcttccgac cccgaactcc accggaggca attgcactgt gtagccgtct gctggagtat acaccaactg cccgactaac 1260 accactggaa gcttgtgcac attcattttt tgatgaatta cgggacccaa atgtcaaact 1320 accaaatggg cgagacacac ctgcactctt caacttcacc actcaagaac tgtcaagtaa 1380 tccacctctg gctaccatcc ttattcctcc tcatgctcgg attcaagcag ctgcttcaac 1440 ccccacaat gccacagcag cgtcagatgc taatactgga gaccgtggac agaccaataa 1500 tgctgcttct gcatcagctt ccaactccac ctgaacagtc ccgagcagcc agctgcacag 1560

gaaaaaccac cagttacttg agtgtcactc agcaacactg gtcacgtttg gaaagaatat 1620 taaaaaaaaa aaaaaaaa 1639

<210> 2 <211> 433 <212> PRT <213> Homo sapiens <400> 2 Met Ser Gly Arg Pro Arg Thr Thr Ser Phe Ala Glu Ser Cys Lys Pro Val Gln Gln Pro Ser Ala Phe Gly Ser Met Lys Val Ser Arg Asp Lys Asp Gly Ser Lys Val Thr Thr Val Val Ala Thr Pro Gly Gln Gly Pro Asp Arg Pro Gln Glu Val Ser Tyr Thr Asp Thr Lys Val Ile Gly Asn 55. Gly Ser Phe Gly Val Val Tyr Gln Ala Lys Leu Cys Asp Ser Gly Glu Leu Val Ala Ile Lys Lys Val Leu Gln Asp Lys Arg Phe Lys Asn Arg Glu Leu Gln Ile Met Arg Lys Leu Asp His Cys Asn Ile Val Arg Leu Arg Tyr Phe Phe Tyr Ser Ser Gly Glu Lys Lys Asp Glu Val Tyr Leu Asn Leu Val Leu Asp Tyr Val Pro Glu Thr Val Tyr Arg Val Ala Arg His Tyr Ser Arg Ala Lys Gln Thr Leu Pro Val Ile Tyr Val Lys Leu Tyr Met Tyr Gln Leu Phe Arg Ser Leu Ala Tyr Ile His Ser Phe Gly .5 - 170 Ile Cys His Arg Asp Tle Lys Pro Gln Asn Leu Leu Asp Pro Asp Thr Ala Val Leu Lys Leu Cys Asp Phe Gly Ser Ala Lys Gln Leu Val Arg Gly Glu Pro Asn Val Ser Tyr Ile Cys Ser Arg Tyr Tyr Arg Ala Pro Glu Leu Ile Phe Gly Ala Thr Asp Tyr Thr Ser Ser Ile Asp Val Trp Ser Ala Gly Cys Val Leu Ala Glu Leu Leu Gly Gln Pro Ile Phe Pro Gly Asp Ser Gly Val Asp Gln Leu Val Glu Ile Ile Lys Val Leu Gly Thr Pro Thr Arg Glu Gln Ile Arg Glu Met Asn Pro Asn Tyr 

Thr Glu Phe Lys Phe Pro Gln Ile Lys Ala His Pro Trp Thr Lys Asp 295 290 300 Ser Ser Gly Thr Gly His Phe Thr Ser Gly Val Arg Val Phe Arg Pro 315 305 310 320 Arg Thr Pro Pro Glu Ala Ile Ala Leu Cys Ser Arg Leu Leu Glu Tyr 325 330 335 Thr Pro Thr Ala Arg Leu Thr Pro Leu Glu Ala Cys Ala His Ser Phe 340 345 350 Phe Asp Glu Leu Arg Asp Pro Asn Val Lys Leu Pro Asn Gly Arg Asp 360 355 365 Thr Pro Ala Leu Phe Asn Phe Thr Thr Gln Glu Leu Ser Ser Asn Pro 370 375 380 Pro Leu Ala Thr Ile Leu Ile Pro Pro His Ala Arg Ile Gln Ala Ala . 385 390 395 400 Ala Ser Thr Pro Thr Asn Ala Thr Ala Ala Ser Asp Ala Asn Thr Gly 405 410 Asp Arg Gly Gln Thr Asn Asn Ala Ala Ser Ala Ser Ala Ser Asn Ser

425

430

Thr

<210> 3

<211> 20

<212> DNA

<213> artificial sequence

420

<220>

.<223> forward primer

<400> 3

ttccagggga tagtggtgtg

<210> 4

<211> 20

<212> DNA

<213> artificial sequence

<220>

<223> reverse primer

<400> 4

tttgctccct tgttggagtt

20

20

<210> 5

<211> 30

WO 2005/083105 PCT/EP2005/001420 4/4

<212> DNA
<213> artificial sequence

<220>
<223> probe

<400> 5

tcagttggta gaaataatca aggtcctggg

30